| Acceptance rate | 46% |
|---|---|
| Time to first decision | 20 days* |
| Time to decision with review | 50 days* |
*Approximate number of days
**The days mentioned above are averages and do not indicate exact durations. The process may vary for each article.
ACTA Pharmaceutica Sciencia
2011 , Vol 53 , Num 4
ANTI-INFLAMMATORY AND ANTINOCICEPTIVE ACTIVITIES OF 6-PHENYL (3’-IMINO-BENZYLIDENE)-4-BENZYLIDENE-2,3,5-TRIHYDRO-3-(2H)-PYRIDAZIN-3-ONE COMPOUNDS
Department of Pharmacy, GRD (P.G) Institute of Management and Technology, Dehradun (U.K), India
Currently used non steroidal anti-inflammatory drugs are one of the most commonly used medications for the treatment of pain and inflammation. Although routine and long-term uses limited due to their gastrointestinal and renal side effects. In order to minimize these side effects, there is increased focus on developing new non steroidal anti-inflammatory drugs. Stimulated by these above findings, our attention has been focused on the new 6-phenyl (3’-imino-benzylidene)-benzylidene-2,3,5-trihydropyridazin-3-one derivatives (5a-5i) were evaluated for antiinflammatory by right hind paw oedema and antinociceptive activity by hot plate and tail flick method respectively. All the compounds (5a-5i), exhibited significant antiinflammatory as well as antinociceptive activity as compared to standard drug indomethacin and aspirin against right hind paw oedema and tail flick, Eddy’s hot plate method in albino rat and mice after intra-peritonially administration of 10 mg/kg and 50mg/Kg body weight dose. The compounds (5a, 5b, 5e, 5g and 5i) showed lesser white spot or gastric ulcer and compounds (5c, 5d, 5f and 5h) no white spot or gastric ulcer in the mucosal layer of the rat stomach as compared to the standard drug (indomethacin), which showed 100% ulceration.
Keywords :
ANTINOCICEPTIVE, ULCER, INFLAMMATION, PYRIDAZINONE